---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-048611"
form_type: "8-K"
ticker: "AIMD"
cik: "0001014763"
company_name: "Ainos, Inc."
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T07:58:34.313503+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ainos signs non-binding MOU with Taiwan Tanabe for VELDONA manufacturing and Taiwan market

## Summary
- Non-binding MOU with Taiwan Tanabe Seiyaku (Mitsubishi Tanabe subsidiary) for exclusive marketing, manufacturing, and marketing authorization of VELDONA in Taiwan.
- Exclusive right of first negotiation for 3 months from Nov 27, 2024, extendable by 3 months with mutual written notice.
- License fees, milestones, and profit-sharing to be agreed in future definitive agreement, contingent on VELDONA NDA approval in Taiwan.
- VELDONA is low-dose oral interferon-alpha for Sjögren's syndrome; prior studies showed symptom alleviation and good safety profile.
- Ainos believes partnership will accelerate global market entry; Sjögren's syndrome market projected billions in 5 years.

## SEC filing metadata
- accession: 0001493152-24-048611
- form_type: 8-K
- ticker: AIMD
- cik: 0001014763
- company_name: Ainos, Inc.
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1014763/000149315224048611/0001493152-24-048611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1014763/000149315224048611/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-048611
- JSON: https://secwatch.observer/filing/0001493152-24-048611.json
- Plain text: https://secwatch.observer/filing/0001493152-24-048611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.